ArticleEuropean journal of nuclear medicine and molecular imaging2026
Correlation of
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHepatocellular carcinoma (HCC) is a heterogeneous malignancy with limited diagnostic and prognostic tools beyond conventional imaging modalities such as CT and ceMRI. Prostate-specific membrane antigen (PSMA) expression, observed in the neoangiogenic endothelial cells of HCC, has emerged as a potential target. This study evaluated the correlation between PSMA biodistribution using [
methodsThis prospective monocentric study enrolled patients with suspected HCC undergoing curative-intent liver resection or transplantation. All participants underwent ceMRI and [
resultsEligible patients were 39, of those 31 were treated surgically. 27/31 (87%) showed PSMA uptake on PET/CT, with a median SUVmax of 12.6 (IQR10.2-16.5). According to IHC intensity analysis, PSMA was expressed in 22/24 (91.6%) of HCC. High PSMA uptake correlated with strong PSMA expression in tumor-associated vasculature (p = 0.028). No significant correlations were found between PET parameters and histological features, such as Edmondson grade or vascular invasion (p > 0.05).
conclusionsPSMA PET/CT offers robust diagnostic accuracy for HCC and correlates with vascular PSMA expression, suggesting potential utility in preoperative staging. These findings support the further exploration of PSMA imaging as a biomarker for HCC.
Indexed as
Identifiers
42734832What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.